Akari Therapeutics (AKTX) had the highest return between January 1, 2014 and January 31, 2014 by a US stock, returning 5,013,984.5%.
| ASSET | DATE | % RETURN |
|---|---|---|
Akari Therapeutics (AKTX) | 1/1/2014 - 1/31/2014 | 5,013,984.51% |
Xenetic Biosciences (XBIO) | 1/1/2014 - 1/31/2014 | 650% |
Live Ventures (LIVE) | 1/1/2014 - 1/31/2014 | 369.21% |
Ainos (AIMD) | 1/1/2014 - 1/31/2014 | 350% |
Capricor Therapeutics (CAPR) | 1/1/2014 - 1/31/2014 | 319.25% |
Scienture (SCNX) | 1/1/2014 - 1/31/2014 | 263.64% |
GT Biopharma (GTBP) | 1/1/2014 - 1/31/2014 | 177.78% |
Ryvyl (RVYL) | 1/1/2014 - 1/31/2014 | 153.52% |
Harrow Health (HROW) | 1/1/2014 - 1/31/2014 | 151.82% |
Opus Genetics (IRD) | 1/1/2014 - 1/31/2014 | 125.49% |
Cytosorbents Crp (CTSO) | 1/1/2014 - 1/31/2014 | 118.75% |
Anixa Biosciences (ANIX) | 1/1/2014 - 1/31/2014 | 103.54% |
Heritage Global (HGBL) | 1/1/2014 - 1/31/2014 | 93.55% |
Digimarc (DMRC) | 1/1/2014 - 1/31/2014 | 91.12% |
Savara (SVRA) | 1/1/2014 - 1/31/2014 | 86.91% |
Neurocrine Biosciences (NBIX) | 1/1/2014 - 1/31/2014 | 84.36% |
CorMedix (CRMD) | 1/1/2014 - 1/31/2014 | 83.06% |
Lightbridge (LTBR) | 1/1/2014 - 1/31/2014 | 81.63% |
CEL-SCI (CVM) | 1/1/2014 - 1/31/2014 | 79.66% |
PharmaCyte Biotech (PMCB) | 1/1/2014 - 1/31/2014 | 76.12% |
Siebert Financial (SIEB) | 1/1/2014 - 1/31/2014 | 76.05% |
Arbutus Biopharma (ABUS) | 1/1/2014 - 1/31/2014 | 75.6% |
Galectin Therapeutics (GALT) | 1/1/2014 - 1/31/2014 | 71.16% |
Identiv (INVE) | 1/1/2014 - 1/31/2014 | 71.15% |
GEE (JOB) | 1/1/2014 - 1/31/2014 | 67.06% |
